Denying renal transplantation to an adolescent medical cannabis user: An ethical case study by Ryan, Jennie E. et al.
Pediatric Transplantation. 2019;23:e13467.	 wileyonlinelibrary.com/journal/petr	 	 | 	1 of 8
https://doi.org/10.1111/petr.13467
© 2019 Wiley Periodicals, Inc.
1  | INTRODUC TION
Medical cannabis is now legal in 33 states, the District of Columbia, 
Guam, and Puerto Rico.1 An estimated 2.5 million Americans use 
cannabis for relief of a variety of illnesses.2 As more patients adopt 
this unconventional therapy, healthcare providers will inevitably 
come across potential transplant recipients utilizing this therapeu‐
tic modality. Transplant providers, from multidisciplinary teams, are 
uniquely impacted by this changing environment.3 Providers are 
tasked with the decision to utilize a precious resource, taking into ac‐
count an individual's long‐term risk. Healthcare providers must take 
on this matter with little guidance from the healthcare literature or 
professional organizations. The International Society for Heart and 
Lung Transplant, a leading source of transplant guidance, recom‐
mends that “patients who remain active substance abusers…should 
not receive heart transplantation.” However, when addressing the 
use of cannabis the recommendation is more ambivalent, stating 
that “it is at best an issue for which no clear direction exists” and 
that “each center will need to develop its own specific criteria for 
adjudicating candidacy for marijuana users”.4
To explore this issue, we present the case of a 20‐year‐old pa‐
tient followed in our pediatric institution, who was recommended to 
the transplant team for renal transplantation and had delay of active 
listing secondary to her medical cannabis use.
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Abstract
Medical cannabis is now legal in over half of the United States. As more patients adopt 
this unconventional therapy, it is inevitable that potential transplant recipients will 
disclose their cannabis use during transplant evaluation. Transplant teams are tasked 
with the decision to utilize a pressure resource, often with little guidance from inter‐
national and national professional organizations. Many healthcare providers remain 
uniformed or misinformed about the risks of cannabis use and organ transplantation. 
In order to illustrate the multifaceted and complex evaluation of transplant patients 
using medical cannabis, this article presents the case of a 20‐year‐old woman recom‐
mended for renal transplant who was originally denied active listing due to her medi‐
cal cannabis use. A review of the literature explores the perceived and actual risks of 
cannabis use in the immunocompromised patient. Furthermore, a discussion of the 
ethics of medical cannabis use and organ transplantation is included with recommen‐
dations for multidisciplinary transplant teams.
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2  | DESCRIPTION OF C A SE
The patient is 20 years old with chronic kidney disease stage V 
secondary to interstitial fibrosis and glomerulosclerosis. She was 
recommended for renal transplant by the nephrology team on 
January 11, 2017. Evaluation for transplantation includes a mul‐
tidisciplinary assessment by the physician and surgical teams, 
anesthesia, registered nurses and nurse practitioners, dieticians, 
social work, and psychology. During her evaluation with the team 
psychologist, the patient disclosed a long‐standing history of de‐
pression and anxiety, beginning in early childhood but becoming 
unmanageable at approximately age 13 (roughly coinciding with 
the onset of her renal disease). Anxiety generally manifested in 
worries about the health of family members and occasional anxi‐
ety attacks while depressive symptoms (dysphoria, fatigue, avo‐
lition, poor concentration, and poor appetite) were triggered by 
life events such as relationship breakups, family stressors, and 
changes in her medical status. When symptoms became unman‐
ageable at age 13, the patient began abusing “triple C's” (Coricidin® 
Cough & Cold; active ingredients: chlorpheniramine maleate 4 mg, 
dextromethorphan hydrobromide 30 mg) approximately once a 
week. She transitioned to weekly alcohol consumption at age 15 
followed by regular cannabis use at age 16. The patient reported 
that she ceased all alcohol and drug use aside from cannabis at 
that time, as cannabis managed her anxiety and depression symp‐
toms effectively without the need for additional substances. She 
had never sought psychiatric care, citing a fear of the side effects 
of psychotropic medications; she participated in three sessions 
of psychotherapy at age 17 but terminated treatment due to per‐
ceived lack of effectiveness.
At the time of the psychosocial transplant evaluation, the pa‐
tient reported regular evening/weekend cannabis use and effective 
management of anxiety and depression symptoms under her current 
regimen. The patient described her use as medicinal rather than rec‐
reational, and evaluation by the transplant psychologist did not yield 
any concern for impairment in psychosocial functioning while ac‐
tively using cannabis to manage anxiety and depression symptoms. 
She was asked to obtain an additional evaluation with an adult psy‐
chiatrist to explore psychotropic medication alternatives to canna‐
bis. Psychiatric evaluation determined that the patient's depression 
and anxiety were “mild” and did not interfere with her functioning, 
understanding, or decision‐making capacity. The potential benefits 
of SSRIs for symptom relief were discussed as well as adverse side 
effects of cannabis use but the patient refused a medication trial and 
continued to express a preference for cannabis management.
The patient had no other physical or social concerns that made 
her ineligible for renal transplantation. She had routinely demon‐
strated a high level of maturity and understanding of her chronic 
condition, and she had been compliant with all of her medical care 
and had taken ownership of her health care. The patient was deemed 
an appropriate candidate for renal transplant by the transplant team 
on September 29, 2017; however, she was listed status seven due 
to continued concerns regarding her medical cannabis use. The 
transplant team agreed to list her as inactive until she obtained a 
legal medical cannabis card in her state, a process which took sev‐
eral months. Once the patient had obtained a medical cannabis card, 
she could obtain cannabis through a local dispensary, as opposed to 
peers through the black market. The transplant team felt that canna‐
bis obtained through a dispensary would be safer for consumption.
3  | CONCERNS VOICED BY THE 
TR ANSPL ANT TE AM
Several concerns were voiced by the transplant team regarding the 
patient's cannabis use and its risk to post‐transplant morbidity and 
mortality. The two primary concerns were risk of Aspergillus infec‐
tion and risk of cannabis contamination with other illicit substances 
such as PCP. One healthcare provider also dissuaded the patient 
from using medical cannabis while encouraging pharmaceutical 
treatments for management of her anxiety. A thorough review of the 
literature was performed to determine the scientific merit of these 
concerns.
3.1 | Risk of Aspergillus infection
Risk of infection is an obvious concern in all patients who are im‐
munocompromised and that concern is often heightened with the 
use of cannabis. Cannabis sativa, whose flowering portion contains 
multiple cannabinoids, has a symbiotic relationship with multiple 
microbes, which, like most plants, occurs mostly at the root level.5 
However, whether the exposure to the natural flora of the can‐
nabis plant causes an increased risk of infection to patients who 
are immunosuppressed is unknown. The main concern voiced by 
the transplant team was risk of Aspergillus infection. Since 1988, 
there have only been two documented case reports of Aspergillus 
infection in transplant recipients that were associated with can‐
nabis use.6,7 When that search was expanded to include all immu‐
nocompromised patients, it revealed only one more case report.8 
There has been one case series of 13 patients with pulmonary 
Aspergillus infection and human immunodeficiency virus, in which 
four patients’ infections were possibly associated with cannabis 
use; however, other predisposing factors included neutropenia 
(due to the disease, to drugs toxic to bone marrow, or both), corti‐
costeroid therapy, previous Pneumocystic jirovecii pneumonia and 
cytomegalovirus disease, and broad‐spectrum antibiotics, includ‐
ing those used in prophylaxis for P jirovecci pneumonia.9 Given 
the growing number of both medicinal and recreational cannabis 
users in the United States, we can only assume that increasing use 
would result in increasing reports of Aspergillus infection in im‐
munocompromised patients, but that is not the case. There have 
been no reports of Aspergillus infection associated with cannabis 
use since 2001, which may be in part due to advances in steriliza‐
tion. Ruchlemer et al10 showed that systemic sterilization of medi‐
cal cannabis can eliminate the risk of opportunistic infections in 
at‐risk patients.
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However, inhalation of cannabis, via smoking and vaporization, 
can still cause harm to immunosuppressed patients. Substantial evi‐
dence has shown a statistical association between cannabis smoking 
and more frequent chronic bronchitis episodes.11 Vaporization is an 
increasingly popular mode of delivery among medical cannabis pa‐
tients.12 Vaporization does not heat the marijuana to the point of 
combustion, therefore exposing users to significantly lower levels 
of toxicants.13 Although vaporization reduces the risk of inhaling 
smoke by‐products such as tar, it may expose the patient to lipid 
inhalation. There is one case report of a renal transplant patient who 
presented with exogenous lipid pneumonia which was considered to 
be secondary to inhaling the vapors of a cannabis, isopropyl alcohol, 
and oil‐based mixture that the patient had been using 2‐10 times 
a day for over 10 years.14 However, this a rare case of home‐pre‐
pared cannabis oil used frequently over many years, and it is unclear 
whether manufactured vaporization cannabis oils and delivery prod‐
ucts carry the same risk. Still, edible cannabis administration may be 
considered a safer route of administration for immunocompromised 
patients.10
The long‐term risk of medical cannabis use in renal transplant 
patients was examined recently by Greenan et al.15 In a retrospec‐
tive review of 1225 renal transplant recipients, the researchers 
found medical cannabis use was not associated with poorer pa‐
tient or kidney allograft outcomes at 1 year. The primary outcome 
of survival at 1‐year post‐transplant did not differ between users 
and non‐users (100% vs 97.7%; P = 0.622). In addition, the propor‐
tion of failed allografts, defined as MDRD GFR < 20 mL/min, did 
not differ between groups (19.7% vs 17.4%; P = 0.62). Ranney et 
al16 performed another retrospective study done in adult patients 
with chronic liver disease being evaluated for transplantation 
over an 8‐year time frame (1999 to 2007). The study compared 
survival between cannabis users and cannabis non‐users. On a 
Kaplan‐Meier survival curve, there was not a significant difference 
in unadjusted patient survival rates in cannabis users vs cannabis 
non‐users. Also, the independent effects of cannabis detection 
in patients with chronic liver disease were assessed and did not 
show a significantly higher hazard of mortality (HR 1.09, 95% CI 
0.78‐1.54).16
We found a lack of evidence to support risk of infection from 
cannabis smoking as a contraindication for renal transplantation. 
On the contrary, novel research now suggests that cannabis may 
be used as therapeutic agent for transplant patients. Cannabis has 
been a target of possible therapeutic use in transplantation due 
to the known expression of CB2 receptors on immune cells and 
end organs. Findings from preclinical studies show a role for CB2 
receptors in protecting against ischemic/reperfusion injury.17,18 
Furthermore, a recent phase II clinical trial that examined the com‐
bination of CBD with standard therapies for GVHD prophylaxis 
showed a statistically significant decrease in GVHD rates in CBD 
users (HR 0.3, P = 0.0002).19 The endocannabinoid system shows 
promise as a possible target for therapies to reduce the immune 
response, with particularly beneficial outcomes for transplant 
patients.3
3.2 | Cannabis contamination with other 
illicit substances
Members of the transplant team voiced a concern that cannabis 
the patient purchased from sources other than state‐run dispen‐
saries could be contaminated with PCP. Marijuana that is soaked in 
PCP is commonly referred to as “wet,” “fry,” or “illy.” While emer‐
gency room visits for PCP intoxication have increased significantly 
in the United States in the past 10 years,20 we could not find a 
single case study in the healthcare literature that reports an indi‐
vidual presenting to the emergency room with accidental or unin-
tentional PCP intoxication from cannabis contamination. Studies 
examining the multiple detrimental effects of PCP contaminated 
cannabis have only identified individuals purposefully ingesting 
the drug,20 and they do not mention any accidental ingestion. An 
expanded search of popular media also did not find significant 
case series of individuals presenting with accidental ingestion of 
PCP contaminated cannabis.
Many healthcare professionals may have apprehension that can‐
nabis procured from sources other than state dispensaries will result 
in unintentional exposure to more harmful substances. However, this 
concern is not substantiated with established evidence. There has 
been only one published case series of illegal cannabis adulterated 
with lead in Germany in 2008.21 Despite common misconceptions, 
there have been no published case reports of cannabis being con‐
taminated or “laced” with other illicit substances, such as fentanyl. 
Currently, a large and serious threat to public health is the contam‐
ination of illicit heroin, cocaine, methamphetamine, and counterfeit 
pills with the powerful narcotic fentanyl, with several warnings being 
issued by the DEA.22 However, there have been no substantiated re‐
ports of cannabis being laced with fentanyl. Furthermore, a majority 
of cannabis users who buy product from non‐state sources obtain 
their cannabis from a trusted source such as a friend, therefore by‐
passing concerns about quality and safety of the product.23
4  | TR ADITIONAL ANTI‐ANXIET Y 
TRE ATMENTS VS C ANNABIS
During her psychosocial evaluation with the team psychologist, the 
patient was educated on empirically supported anxiety treatment 
alternatives to cannabis. CBT is a gold standard, short‐term psycho‐
therapy approach that targets thoughts and behaviors that lead to 
maladaptive emotional responses. CBT emphasizes the use of ex‐
posures and coping skills, such as self‐talk and relaxation, to unlearn 
anxious responses to stimuli. Compared to psychological or phar‐
macological placebo, CBT is consistently found to be an efficacious 
intervention.24 While the patient was initially open to participating 
in CBT, she ultimately declined psychotherapy services as her symp‐
toms were well managed with her current cannabis regimen. The 
team psychologist did not express concern with her decision to forgo 
treatment as current symptoms did not interfere with her function‐
ing or judgment.
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One member of the transplant team, as well as an external adult 
psychiatrist, recommended that the patient use traditional pharma‐
ceuticals for management of her anxiety, as opposed to cannabis. 
This recommendation presents two concerns. First, the patient's 
preference was for cannabis. The patient reported to several health‐
care providers that cannabis was more effective at treating her anx‐
iety and she expressed concern about the possible side effects of 
psychotropic medications. A competent adult patient with decisional 
capacity should always maintain the right to choose which medical 
treatment works best for them. Second, traditional pharmaceuticals 
used for management of anxiety in pediatric patients, while effec‐
tive, have significant risks that should not be ignored.
The largest randomized control trial to date evaluating treatment 
modalities for pediatric anxiety is the CAMS.25 The study included 
three different experimental groups: sertraline only, CBT only, com‐
bination therapy, and placebo. The study showed that both CBT 
and sertraline were effective in reducing childhood anxiety, but 
combination of the two therapies had a superior response rate. A 
Cochrane Review from 2009 also showed significantly greater treat‐
ment response with medication vs placebo.26 However, drug‐related 
adverse events were significantly more frequent in medication group 
vs placebo and accounted for almost twice as many withdraws. 
Much attention has been brought to the multiple meta‐analyses and 
systemic reviews which have shown increased risk of suicidality,27,28 
suicidal ideation, and suicide attempts29 in children and adolescents 
treated with antidepressants. These studies prompted the FDA to 
place a black box warning on the labels of all antidepressants in 
2004. Two years following the black box warning, there was a sig‐
nificant reduction in antidepressant use; 20% for children, 31% for 
adolescents, 21.4% for young adults, and 14.5% for adults.30 This 
decrease could reflect changing attitudes of prescribers as well as 
patients and parents.31 It is reasonable that patients and parents, 
aware of the multiple side effects and risks associated with antide‐
pressants, will be reluctant to adopt this modality for management 
of anxiety. Furthermore, long‐term data regarding safety and effi‐
cacy of antidepressants for treatment of anxiety are lacking.26
Benzodiazepines are often used as second‐line pharmacother‐
apy for management of acute anxiety; however, there is no con‐
trolled evidence for their effectiveness in pediatric patients.26,32 
Furthermore, there are significant concerns for dependence associ‐
ated with benzodiazepine use. Benzodiazepines have higher rates of 
both dependence and mortality then does cannabis. Benzodiazepine 
use for as little as 3 to 6 weeks, even while adhering to therapeutic 
doses, is associated with the development of physical dependence, 
with between 15% and 44% of chronic benzodiazepine users ex‐
periencing protracted moderate to severe withdrawal symptoms 
upon cessation including emergent anxiety and depressive symp‐
toms.33‐35 Cannabis dependence is observed at lower rates, with 
only 9% of individuals who use cannabis becoming dependent on 
it.36,37 Furthermore, benzodiazepines have a significantly higher risk 
of fatal overdose then cannabis. Benzodiazepine overdose has been 
steadily increasing over the past 10 years.38 The latest available data 
from the National Institute of Health showed that 8791 Americans 
died from benzodiazepine overdose in 2015, while no Americans 
died of cannabis overdose.38 When recommending a drug to a pa‐
tient, it is essential that prescribers assess the available data regard‐
ing safety and efficacy, and in this case, cannabis was both the safer 
and more effective drug for this patient.
Because of federal restrictions on cannabis, there are few ran‐
domized controlled trials examining the efficacy and safety of can‐
nabis for treatment of anxiety. Several small studies have shown 
both anxiolytic and anxiogenic effects from cannabis, based on 
the cannabinoid being studied and the dose at which it was ad‐
ministered. Intravenous THC has been shown to increase anxious 
scores on the VAS.39 Inhaled THC at high concentrations (3.6%) 
has been shown to increase anxious scores on VAS, while lower 
concentrations (1.8%) had no significant effect on VAS anxious 
scores.40
Low‐dose oral THC (7.5 mg) has been shown to produce sub‐
jective stress‐relieving effects, while higher doses (12.5 mg) may 
increase negative mood.41
While THC has shown variable effects on anxiety, CBD has 
consistently been shown to reduce anxiety. A preliminary dou‐
ble‐blind, placebo‐controlled cross‐over study comparing a single 
dose of CBD (400 mg) to placebo was conducted in 10 treatment‐
naive men with generalized social anxiety disorder. Participants 
rated their anxiety using the VAMS. There was significantly re‐
duced VAMS scores vs placebo on the anxiety factor (P < 0.001).42 
Another study investigating the use of CBD for treatment of social 
anxiety disorder also found significantly decreased VAMS scores 
vs placebo on the anxiety factor (P < 0.012).43 CBD has also been 
shown to decrease VAS factor anxiety scores after public speak‐
ing.44 However, all these studies were limited by small sample 
sizes. Further larger randomized control trials are needed to as‐
sess safety and efficacy of various cannabinoids for the treatment 
of anxiety.
While randomized control trials are lacking, much information 
has been extrapolated from epidemiological data. Much of the 
debate regarding the relationship of cannabis and anxiety centers 
around the idea of “self‐medication”. In various studies, numerous 
subjects have reported using cannabis to relax, to cope with stress, 
and to reduce anxiety.45‐51 Relaxation and relief of tension have been 
reported as the most common reasons for using cannabis.47,49,51 
Individuals living in states with medical cannabis laws self‐medicate 
with cannabis at higher rates than those not living in medical canna‐
bis states (P = 0.02).52 These findings suggest that access to canna‐
bis may be an important contributor to therapeutic use.
5  | ETHIC AL CONSIDER ATIONS
5.1 | Four principles
This case presented several ethical dilemmas. The four principles 
of medical ethics include the following: respect for autonomy, be‐
neficence, non‐maleficence, and social justice. When applying the 
principles of autonomy and beneficence to this case, one could make 
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the argument that this young woman had the right to choose can‐
nabis (autonomy) and that it is in her best interest to move forward 
with renal transplantation (beneficence). However, the principle of 
non‐maleficence could be applied to argue against medical cannabis 
use. Non‐maleficence requires that healthcare providers first “do no 
harm,” and that our interventions will not have further devastating 
outcomes for a patient. This patient had end‐stage renal disease, and 
while a renal transplant would provide her the most optimal out‐
come, she can live for many years without a renal transplant receiv‐
ing dialysis. But if the team agreed to proceed with transplant and 
she developed complications secondary to her cannabis use, she 
could potentially have a life‐threatening outcome. Additionally, this 
patient engaged in alcohol and OTC medication abuse to manage 
her anxiety and depression before she transitioned to cannabis use. 
Requiring her to cease engaging in an effective mood management 
treatment to become transplant eligible could increase the likelihood 
of a return to high‐risk activities. What the team must ask is if her 
cannabis use places her at any increased risk as compared to non‐
cannabis users? As discussed in this report, the evidence does not 
support increased risk. The principle of justice furthers this argu‐
ment by advocating that this patient be evaluated fair and equally 
as other non‐cannabis users. However, stigma surrounding the use 
of cannabis often introduces implicit bias from healthcare providers.
The decision by the transplant team to allow active listing for 
renal transplantation only after the patient enrolled in the state‐
sponsored medical cannabis program settled the concern about 
contaminated product; however, it raises several ethical concerns 
surrounding social justice. First, this patient was fortunate to live in 
a state that had an active medical cannabis law. However, consider 
if she were in a state that did not have legal access to medical can‐
nabis. Requiring that a medical cannabis user register with a state 
program prior to active transplant listing creates a disparity between 
patients in states where this is and is not an option. Furthermore, 
state‐level laws that govern medical cannabis use are idiosyncratic 
and frequently contradictory. Conditions that would qualify a pa‐
tient for medical cannabis in one state may not qualify them in other, 
for example, the use of cannabis to treat medication‐resistant opioid 
addiction. In addition, only 8 out of 33 states allow nurse practi‐
tioners to certify a patient for medical cannabis,53 which may limit 
access for many Americans in rural and low socioeconomic commu‐
nities who rely on nurse practitioners as their primary providers. 
Finally, state programs often have a significant registration fee, and 
the cost of cannabis through state dispensaries is greater than from 
non‐state sources.54 For patients with chronic kidney disease, this 
cost differential may prohibit registration with the state medical 
cannabis program. Discriminating against those who are unable to 
afford state cannabis programs violates the ethical principle of so‐
cial justice. The inconsistencies and contradictories of state cannabis 
laws will require federal action to remediate. While federal law main‐
tains cannabis prohibition, the significant social justice concerns will 
not be resolved.
While federal prohibition is maintained, hospital systems 
themselves will be faced with multiple ethical dilemmas related to 
cannabis use in the inpatient setting. Despite legalization of med‐
ical and recreational cannabis in several states, many, but not all, 
hospitals prohibit the use of cannabis products within their insti‐
tutions due to the theoretical risk to their CMS certification. Our 
institution is located in the northeast region of the country and 
does not permit patients or caregivers to bring cannabis into the 
hospital, despite its legality in the state. However, at least two 
other pediatric hospitals in bordering states do allow patients and 
caregivers to bring cannabis products into the hospital. This again 
presents a violation to the principle of social justice where access 
to cannabis products is limited not only by the patient's state, but 
also the policies of the individual institutions within that state. 
Recommending a patient transfer their care to an outside hospital 
that allows cannabis products places a burden on the patient and 
also fragments their care. It is also unlikely that insurance would 
approve such a transfer of care, therefore placing the patient and 
family at financial risk.
5.2 | Stigma
Illicit drug use is associated with a high degree of stigma from health‐
care providers in a variety of settings.55‐57 Adult medical cannabis 
users have reported stigmatization related to their use of cannabis as 
a medication.58‐60 Stigma may be related to the “blurred boundary” 
between medicinal use and recreational use.60 During team meetings 
and discussions regarding this patient, some members of the team re‐
ferred to the patient's cannabis use as recreational, although she never 
reported recreational use. Incorrectly labeling a patient as a recrea‐
tional cannabis user can introduce bias and implicit stigmatization. As 
healthcare providers, we must recognize our own bias regarding can‐
nabis and assure that it does not interfere with our decision‐making.
Beyond stigma, healthcare providers may have legal concerns re‐
garding the recommendation for cannabis use and the administration 
of cannabis to patients. Physicians and nurse practitioners with DEA 
certification may fear investigation if they allow their patients to uti‐
lize a schedule one drug. Nurses working at the bedside may fear dis‐
ciplinary actions against their licensure if they administer a schedule 
one drug. Furthermore, all healthcare providers may be uncomfort‐
able with their patients utilizing an herbal therapy such as cannabis 
that has significant variability and no established dosing guidelines.
5.3 | Laws against discrimination for medical 
cannabis patients
Several states have enacted legislation prohibiting hospitals from 
determining a patient's suitability for transplant based solely on the 
basis of medical cannabis use. California,61 Washington,62 Illinois,63 
Arizona,64 Delaware,65 and New Hampshire66 have all expanded their 
medical cannabis bills to include antidiscriminatory sections, designed 
to protect medical cannabis patients. However, these laws stipulate 
that the medical use of cannabis must be recommended by a health‐
care provider. Patients using medical cannabis outside the guidance of 
a healthcare professional may not be entitled to the same protections. 
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The patient presented in this case study was not protected under the 
Delaware Medical Marijuana Act until she received her medical can‐
nabis license.
6  | CONCLUSION
This case study demonstrates that despite traditional perception, 
convincing evidence of direct harm to a renal transplant patient by 
cannabis inhalation or ingestion has yet to be established. When ex‐
amining the risk vs benefit ratio for our patients in situations such as 
these, it is imperative that we rely upon the established evidence to 
direct our decision‐making. In this case, the patient's listing status 
was affected for 5 months and the decision to actively list her was 
only possible because of local laws and the patient's financial means. 
While a handful of medical cannabis states have antidiscriminatory 
legislation to protect medical cannabis patients, most states do not. 
With the growing number of medical cannabis patients, hospitals 
and transplant teams will be forced to address the issue of cannabis 
use and transplantation, often without the guidance of national and 
international transplant societies. In this case study, the use of a mul‐
tidisciplinary team aided in the decision‐making process; however, 
an ethics consult was warranted given the complexities of the case. 
We recommend that transplant patients using medical cannabis be 
evaluated with the same objectivity as non‐cannabis using patients. 
Given the complexities and challenges of state and federal laws 
pertaining to medical cannabis, we recommend the use of an ethics 
consult to aid in the team's decision‐making process. The role of an 
ethics consult can be particularly beneficial in states where medical 
cannabis remains illegal, and patients are using medical cannabis illic‐
itly. These situations present significant legal concerns for transplant 
teams and patients who choose to disclose their medical cannabis 
use or have their use discovered through urine drug screening. As 
stated prior, the ethical and legal concerns regarding cannabis use 
and transplant will remain unresolved until state and federal laws 
are congruent. There is a significant need for further research into 
the therapeutic benefits of cannabis; however, regulatory barriers, 
including the classification of cannabis as a schedule I drug, impede 
the advancement of that research.11 We therefore agree with the 
recommendations of the American Academy of Pediatrics67 and the 
American Nurses Association68 to reschedule cannabis to schedule 
II in order to allow further research into its therapeutic value.
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